FDA to weigh lifting restrictions on some MAHA-favored peptides

The FDA is considering lifting restrictions on certain peptides favored by MAHA, with an advisory panel meeting in July to discuss allowing compounding pharmacies to manufacture these peptides for conditions like ulcerative colitis, wound healing, and obesity. The decision aims to address safety concerns while expanding access to treatments.